What's Happening?
Novo Nordisk has reported that its next-generation obesity drug candidate, CagriSema, achieved over 20% weight loss at lower doses in a Phase 3 trial. Data from the REDEFINE 9 study, presented at ObesityWeek 2026, showed that patients receiving weekly
doses of 1 mg and 1.7 mg of the cagrilintide and semaglutide combination lost 21% and 20.7% of their body weight, respectively, over 68 weeks. This compares to a 2% weight loss in the placebo group. These results are consistent with the 22.7% weight loss observed in the REDEFINE 1 trial, where patients received up to 2.4 mg. Analysts from BMO Capital Markets have lauded the 'strong efficacy' of these lower doses, suggesting that CagriSema can deliver substantial weight loss across a range of dosages. The drug is currently under review by the FDA, with a decision anticipated by the end of the year.
Why It's Important?
The promising results for CagriSema, particularly at lower doses, are significant for the U.S. obesity treatment landscape. With obesity being a major public health concern, a new highly effective treatment option could impact millions of Americans. The ability to achieve substantial weight loss with lower doses might improve the drug's tolerability profile, potentially reducing side effects like nausea and vomiting, which were reported in both REDEFINE 1 and REDEFINE 9. This could lead to better patient adherence and broader adoption. Furthermore, the introduction of CagriSema could intensify competition in the rapidly growing weight-loss drug market, currently dominated by drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Increased competition could drive innovation, potentially leading to more accessible and diverse treatment options for patients struggling with obesity.
What's Next?
Novo Nordisk is preparing for the potential launch of CagriSema, with an FDA approval decision expected by the end of the year. The company aims to leverage its established physician familiarity and extensive clinical data from semaglutide to support the new drug's introduction. The amylin component of CagriSema is expected to offer differentiated benefits compared to existing therapies. If approved, the focus will shift to market access, pricing strategies, and patient uptake. The ongoing 80-week Phase 3 REDEFINE 11 trial will further explore weight loss, potentially providing more insights into the drug's full profile. The market will also be watching how CagriSema competes with Eli Lilly's Zepbound, especially as both companies continue to expand their offerings in the obesity space.
Beyond the Headlines
The development of highly effective weight-loss medications like CagriSema represents a paradigm shift in how obesity is managed, moving beyond lifestyle interventions alone. This could lead to a re-evaluation of obesity as a chronic disease requiring medical intervention, similar to other chronic conditions. The potential for significant weight loss could have far-reaching public health implications, including a reduction in obesity-related comorbidities such as type 2 diabetes, cardiovascular disease, and certain cancers. However, widespread adoption of such therapies also raises questions about healthcare costs, insurance coverage, and equitable access. The long-term effects of these medications, including their impact on overall health and potential side effects over many years, will also be a critical area of ongoing research and public health discussion.













